IL13 and asthma: Tralokinumab, a fully human monoclonal antibody neutralizing IL-13 has proven effectiveness in atopic dermatitis, however, a randomized double-blind clinical trial in patients with corticosteroid-dependent asthma failed to demonstrate oral corticosteroid-sparing effects [206] and hence further development for asthma has been discontinued.